UK markets close in 2 hours 27 minutes

Palatin Technologies, Inc. (PTN)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
2.0400+0.0400 (+2.00%)
At close: 04:00PM EDT
2.0400 0.00 (0.00%)
Pre-market: 08:39AM EDT

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
https://palatin.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees34

Key executives

NameTitlePayExercisedYear born
Dr. Carl Spana Ph.D.Co-Founder, President, CEO & Director979kN/A1962
Mr. Stephen T. Wills CPA, MSTCFO, COO, Executive VP, Treasurer & Secretary910.55kN/A1957
Burns McClellanVice President of Investor RelationsN/AN/AN/A
Mr. Stephen A. Slusher Esq.Chief Legal OfficerN/AN/AN/A
Dr. Michael B. Raizman M.D.Chief Medical OfficerN/AN/AN/A
Mr. James E. HattersleySenior Vice President of Business DevelopmentN/AN/A1960
Mr. John Dodd Ph.D.Senior Vice President of Preclinical DevelopmentN/AN/AN/A
Mr. Robert JordanSenior Vice President of Program OperationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Corporate governance

Palatin Technologies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.